Texas State University Enters Into Research Agreement With Orizon Research

Texas State University and Orizon Research Institute have entered into an agreement that will permit university researchers to continue efforts through in-vivo testing to further determine the potential and effectiveness of ALKA-V6.

The company claimed that ALKA-V6 is a compound that has shown remarkable ability to kill cancer cells and inhibit the HIV virus in laboratory experiments.

The research is expected to evaluate the effects of ALKA-V6 on animal organisms and will be highly replicated with the goal of moving knowledge about the compound toward eventual FDA approval.

Troy Chesnut, managing member of Orizon Research Institute, said: “We are excited to move our research from artificial laboratory systems to animal organisms. These next 18 months of research should confirm previous studies and provide more answers about this promising product.”